John Mascarenhas, MD, MS: Continuing to Evaluate Pacritinib for Myelofibrosis

Dr. Mascharenhas discusses results from the randomized phase III PERSIST-2 trial of the JAK2 inhibitor pacritinib in patients with myelofibrosis and thrombocytopenia, which was put on clinical hold in February 2016.

SHARE